Its affinity was reduced to one-tenth, however. The alkylation of M 2 D103N by BR384 was competitively inhibited by N-methylscopolamine and allosterically inhibited by gallamine.
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INTRODUCTION Allosteric interactions at G protein coupled receptors are often studied by measuring the effect of the putative modulator on the binding of an orthosteric radioligand at equilibrium (Christopoulos, 2000) . This approach has many advantages, but is limited in discriminating between competitive inhibition and high negative cooperativity. This requires the use of a radioligand concentration in proportion to the negative cooperativity, which may be unfeasible because of high cost and nonspecific binding.
Kinetic analysis is an alternative when the negative cooperativity is great and the modulator acts only at the allosteric site (Lazareno and Birdsall, 1995) . For in most cases, only an allosteric modulator should affect the dissociation kinetics of the radioligand. In situations where the modulator acts at both the allosteric and orthosteric sites, it may be impossible to determine kinetically to which site the modulator binds with higher affinity (Birdsall and Lazareno, 2005) . At muscarinic receptors, the problem is confounded because occupancy of the allosteric site often prevents the transit of radioligands to the orthosteric site (Proska and Tucek, 1994) . Thus, the effect of an allosteric modulator on kinetic rate constants often includes two components -an inhibition of radioligand transit to and from the binding pocket and a selection of a receptor conformation with altered kinetics. Only the latter is allosteric because it represents a change in the equilibration of receptor conformations. Using kinetic and equilibrium methods, it would be impossible to discriminate a high affinity, highly negatively cooperative modulator from a ligand with no cooperativity, but capable of binding to the orthosteric and allosteric sites with high and low affinity, respectively (Birdsall and Lazareno, 2005 ).
An alternative approach involves dividing the assay into two phases (Ehlert and Jenden, 1985; Suga et al., 2008) . In the first phase, the putative modulator equilibrates with the receptor and a site-directed electrophile (primary probe) for the orthosteric site. If the latter is small and has an affinity constant not much higher than 10 7 M -1 , it should equilibrate rapidly with the receptor and modulator if its rate constant for alkylation is much slower. In the second phase, This article has not been copyedited and formatted. The final version may differ from this version. for the concentration-dependence of their receptor protection. The working concentration range of the primary probe can be much greater than that of a radioligand in the conventional equilibrium analysis of allosterism. Also, because the interacting ligands are likely to be in equilibrium during the first phase of the experiment, potential effects of the allosteric ligand on the access and egress of the primary probe to the orthosteric site are eliminated. Thus, the method represents a quasi-equilibrium approach with an extended concentration range for the primary orthosteric probe.
We have used this approach to determine how allosteric and orthosteric ligands modify M 1 and M 2 muscarinic receptor alkylation by acetylcholine mustard (AChM) and a nitrogen mustard derivative of McN-A-343 (BR384; 4-[(2-bromoethyl)methyl-amino]-2-butynyl N-(3-chlorophenyl)carbamate) (Suga et al., 2008; Suga and Ehlert, 2010; Figueroa et al., 2010) . We found that the orthosteric ligands, N-methylscopolamine (NMS) and acetylcholine (ACh) competitively inhibit receptor alkylation, whereas the allosteric ligands, gallamine and WIN 51,708 (17-ß-hydroxy-17-α-ethynyl-5-α-androstano[3,2-ß] pyrimido[1,2-α]benzimidazole), had partial or no effect, which is consistent with an allosteric action. We also found that the M 1 and M 4 selective agonist, carbamoyl]oxy]-2-butynyl] trimethylammonium), competitively protected M 1 and M 2 receptors from alkylation. These results are consistent with a recent modeling study suggesting that the binding site for McN-A-343 overlaps with the orthosteric site (Valant et al., 2008) .
In this report, we used mutagenesis to investigate which amino acid side chains in M 1 and M 2 muscarinic receptors are involved in the covalent binding of AChM and BR384. Our results suggest that the two nitrogen mustard analogs alkylate at least one residue in addition to aspartic acid 3.32 (numbering scheme of Ballesteros and Weinstein (1995) ) in M 1 and M 2 receptors and that the additional site is located near or within the orthosteric-binding pocket.
This article has not been copyedited and formatted. The final version may differ from this version. The reagents for organic synthesis were obtained from Sigma-Aldrich. AChM was synthesized as described previously (Suga, et al., 2008) . The boiling point (65 -67°, 0.5 mm) of the free base of AChM was consistent with that reported by Jackson and Hirst (1972) (65 -66°, 0. 5 mm). BR384 was synthesized by the method of Ringdahl et al. (1990) . The melting point (120 -122°) of the oxalate salt of the immediate precursor to BR384 (4-[(2-Hydroxyethyl)methylamino]-2-butynyl N-(3-Chloropheny1)carbamate was similar to that described previously (Ringdahl et al., 1990) (121 -122°) . Upon dissolution in 10 mM sodium phosphate buffer, pH 7.4, the product liberated an equivalent of halide and formed a maximal aziridinium ion concentration (52.2%) similar to that reported previously (Ringdahl et al., 1990) (54%). Bromide and aziridiridinium ions were estimated by titrations with silver chloride and thiosulfate, respectively (Skoog and West, 1965) .
Site-Directed Mutagenesis:
The human M 1 and M 2 muscarinic receptor cDNAs, cloned into a modified Okayma-Berg expression vector (pCD-hM 1 and pCD-hM 2 ), were provided by Dr. Tom
Bonner at the National Institute of Mental Health (Bethesda, MD). Point mutations were This article has not been copyedited and formatted. The final version may differ from this version. were obtained from Acadia Pharmaceuticals (San Diego, CA) and cultured as described previously (Suga et al., 2008) . Human embryonic kidney 293 (HEK 293) cells were cultured in Dulbecco's Modified Eagle Medium with high glucose plus L-glutamine supplemented with 10% fetal calf serum, 3.7 g/l sodium bicarbonate and penicillin-streptomycin (100 units/ml and 100 µg/ml, respectively) at 37°C in a humidified atmosphere with 5% CO 2 /95% air. The plasmids encoding mutated muscarinic receptors were transfected into HEK 293 cells using
GeneJammer following the manufacturer's protocols. After transfection, the cells were incubated for 48 h and harvested for assays.
Preparation of cellular homogenates: CHO hM 1 , CHO hM 2 or HEK 293 cells expressing mutant muscarinic receptors grown to confluence in 100 mm dishes (Corning Incorporated, Corning, NY) were scraped into binding buffer (20 mM Na Hepes, pH 7.4, 100 mM NaCl and 10 mM EDTA) using a Teflon spatula. The mixture of buffer and cells was centrifuged (1,247 x g, 10 min) and the supernatant discarded. The pellet was homogenized in binding buffer using the Polytron (Brinkmann Instruments, Westbury, NY) at setting #4 for approximately 10 sec. mM phosphate buffer at pH 7.4 (pH after dissolution) for 15 and 5 min, respectively, to allow formation of the reactive aziridinium ion as described previously (Suga et al., 2008; Suga and Ehlert, 2010) . The cyclized solutions were placed on ice and used as soon as possible. ]NMS was measured using a filtration assay as described previously (Suga et al., 2008) . Residual binding in the presence of atropine (10 µM) was defined as nonspecific.
This article has not been copyedited and formatted. The final version may differ from this version. aziridinium ion first forms a reversible complex with the receptor (XR or XRA), which converts to a covalent complex (X-R or X-RA) at a relatively slower rate as characterized by the rate constant, k 1 . We developed equations that describe this model under the condition where the concentration of the aziridinium ion is constant during the incubation and the rate of receptor alkylation is slow relative to the reversible binding step (Suga et al., 2008) . In the absence of the allosteric modulator, the loss of receptor binding as a function of time is described by
in which Y t denotes the free, unalkylated receptor at time t, Y o, the total amount for receptors at the start of the incubation, and b, the proportion of the receptor population that is insensitive to aziridinium ion. In the presence of the allosteric modulator, the loss of receptor binding as a function of time is described by:
In the presence of a competitive inhibitor, the loss of receptor binding as a function of time is described by:
in which I denotes the concentration of competitive inhibitor and K i , its affinity constant. The appropriate kinetic data with AChM were fitted to equation 1 -3 because the aziridinium ion of AChM is stable.
We also developed an analogous series of equations (4 -6) to account for the condition where the aziridinium ion decays during the reaction with the receptor (Suga and Ehlert, 2010) .
The corresponding equation for the loss of receptor binding as a function of time is
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in which τ x denotes the time constant for the decay of the aziridinium ion and X 0 denotes the initial concentration of the cyclized mustard analog. In the presence of the allosteric modulator, the loss of receptor binding as a function of time is described by:
The appropriate kinetic data with BR384 were fitted to equation 4 -6 setting the time constant for the decay of the aziridinium ion to (0.07 min -1 ) as described previously.
We also used a more empirical approach to display the effects of inhibitors on the observed rate constant for alkylation (Suga et al., 2008) . First, the observed rate constant for receptor alkylation (k obs ) by the mustard analog was estimated in the absence and presence of the various concentrations of the allosteric modulator or competitive inhibitor using an exponential decay equation. In the case of BR384, only the data obtained during the first eight minutes of alkylation were used to avoid error associated with the decay of the aziridinium ion. In the presence of a competitive inhibitor, the time constant for receptor alkylation is described by:
in which R denotes the ratio of the time constants for receptor alkylation in the absence (τ) and presence (τ') of the competitive inhibitor, respectively. The time constant is defined as the This article has not been copyedited and formatted. The final version may differ from this version. 
The log R values for BR384 measured in the presence of increasing concentrations of either NMS or gallamine were plotted against the concentration of the inhibitor, and equations 8 or 9
were fitted to the data to illustrate the nature of the interaction.
The data for the inhibition of [ 3 H]NMS binding to wild type and D103N M 2 receptors by gallamine was analyzed to estimate the affinity constant (K NMS ) and cooperativity factor (α) of gallamine. The cooperativity factor was estimated as described previously (Ehlert, 1988) :
in which Y' denotes the estimate of the fractional [ 3 H]NMS binding in the presence of saturating concentrations of gallamine. The affinity constant of gallamine was also estimated as described previously (Ehlert, 1988 ): (Spalding et al., 1994) . We also investigated D 3.26
(M 1 D99 and M 2 D97) because this acidic residue may be part of a peripheral ligand-docking site (Jakubik et al., 2000) . The E2 loop of muscarinic receptors is thought to be linked to the top of TM3 through a disulfide linkage (Curtis et al., 1989) , which tethers a triad of acidic residues in the E2 loop of the M 2 receptor (E172, D173 and E175) near the top of the orthosteric binding pocket. Hence, these residues were investigated. In the ß 2 -adrenoceptor structure (Cherezov et al., 2007) , the residue cognate to M 1 C407 and M 2 C429 lies close to D 3.32. Given the reactivity of the thiol group of cysteine, we investigated the corresponding M 1 C407A and M 2 C429A mutants. We also investigated M 2 C413A and M 2 C416A because of their reactivity even though they are in E3 and presumably not part of the orthosteric binding pocket.
While tryptophan and the hydroxyl groups of serine and tyrosine are not expected to react with the aziridinium ions of the mustard analogs, it is conceivable that other nearby residues in the receptor might enhance their reactivity. Thus, we investigated serine, tyrosine and tryptophan at positions in the M 2 sequence that are expected, based on the ß 2 -adrenoceptor structure, to be close to D103 or to line the central aqueous binding pocket. We also investigated additional residues in the M 2 receptor that may be part of the allosteric site or the peripheral docking site. Figure 2 illustrates the residues in the M 2 receptor that were investigated.
This article has not been copyedited and formatted. The final version may differ from this version. receptor, and its kinetics were characterized by a log affinity constant of 5.14 ± 0.08 and a rate constant for alkylation of 0.95 ± 0.13 min -1 (Figure 5c ). At the M 1 D105N mutant, the log affinity constant of BR384 was less (3.44 ± 0.47), and its rate constant for alkylation was 0.88 ± 0.29 min -1 (Figure 5d ). The estimates of the residual unalkylated receptor populations for AChM at M 1 and BR384 at M 1 and M 1 D105N were 10.8 ± 1.3%, 12 ± 2.9% and 10.1 ± 4.7%, respectively.
AChM readily alkylated the wild type M 2 receptor, and the analysis of the kinetic curves yielded a log affinity constant of 4.41 ± 0.05 and a rate constant for alkylation of 0.24 ± 0.05 min -1 (Figure 6a ). Alkylation of the M 2 receptor was greatly inhibited in the D103N mutant (Figure 6b) , and it was difficult to obtain accurate parameters for AChM. BR384 also readily alkylated the wild type M 2 receptor, and analysis of its kinetics yielded an affinity constant of This article has not been copyedited and formatted. The final version may differ from this version. (Figure 6c ). The M 2 D103N mutant was alkylated by BR384 with a greater rate constant 3.30 ± 0.80 min -1 ), but the log affinity constant of was reduced to 3.58 ± 0.13 (Figure 6d ).
The data suggest that both M 1 D105N and M 2 D103N are alkylated by AChM and BR384 but with reduced affinity and, in the case of AChM, with a greatly reduced rate constant.
Estimation of affinity using equilibrium binding:
To obtain an independent estimate of the affinity constants of the aziridinium ions of AChM and BR384 for wild type and D3.32N mutant receptors, we measured the competitive inhibition of the binding of [ Analysis of the data showed that the reduction in the affinity constant of [ residue, but with a much slower rate constant. To determine whether the non-D103 residue in the M 2 receptor is part of the orthosteric binding pocket, we investigated how the orthosteric ligand, NMS, and the allosteric ligand, gallamine, interfered with its alkylation. In these experiments, the rate of alkylation of M 2 D103N by cyclized BR384 (0.1 mM) was measured in the absence and presence of various concentrations of either NMS or gallamine.
NMS caused a concentration-dependent slowing and near cessation of the alkylation of M 2 D103N by BR384 (Figure 8a ). Increasing the concentration of gallamine also slowed the rate of alkylation, but the effect of gallamine approached a limit, which is consistent with an allosteric mechanism (Figure 8b ). Global nonlinear regression analysis yielded a good fit of the competitive (equation 6) and allosteric (equation 5) models to the data with NMS and gallamine, respectively. The competitive effect of NMS is apparent in Figure 8c where the increase in the time constant for alkylation increases proportionately with the NMS concentration. In contrast, gallamine's effect reaches a plateau at high concentrations (Figure 8d ). Regression analysis of the data yielded an estimate of the log affinity constant of NMS to be 7.62 ± 0.04. This value agrees with that obtained in the NMS/[ 3 H]NMS competition experiment summarized in Table 1 .
The estimates of the log affinity (log K 2 ) and cooperativity constant (log α ) for gallamine were 5.50 ± 0.06 and -1.31 ± 0.05, respectively.
To obtain an independent estimate of the affinity constant for gallamine, we measured the inhibition of [ Gallamine did not cause a complete displacement of [ 3 H]NMS binding at high concentrations, which is consistent with an allosteric mechanism. Analysis of the data using equations 10 and 11
This article has not been copyedited and formatted. The final version may differ from this version. One can never be certain in this type of mutagenesis study that the mutation prevents alkylation by eliminating the nucleophilic side chain involved in covalent bond formation with the mustard derivative. Rather, it could cause a structural change in the receptor that greatly reduces the reversible binding characteristics of the aziridinium ion so that it is unable to bind to the receptor in the first place. We attempted to reduce this potential problem by making conservative mutations.
We assume that if the aziridinium ions of AChM or BR384 alkylate muscarinic receptors then they must occupy the receptor reversibly before alkylating it. If so, then the rate of receptor alkylation should be proportional to receptor occupancy. This hypothesis is consistent with our prior observations on the alkylation of M 1 and M 2 receptors by various concentrations of AChM and BR384 in intact cells (Suga et al., 2008; Suga and Ehlert, 2010; Figueroa et al., 2010) . The rate of receptor alkylation was proportional to receptor occupancy as judged by the ability of the aziridinium ions to inhibit It has a potency about one-fourth that of ACh in the guinea pig ileum when measured in the presence of physostigmine to prevent cholinesterase activity (Robinson et al., 1975) . Another explanation is the presence of a population of a high affinity receptor-G protein complex in M 2 CHO cell homogenates. We have previously argued that this complex is alkylated at a slower rate (Suga et al., 2008) . This site would be more difficult to detect in alkylation experiments, where the data are determined mainly by the more predominant, rapidly alkylated receptor and it is thought to act as a counter ion for the cationic neurotransmitter (Hulme et al., 2003) . In addition, [ 3 H]AChM is known to alkylate D105 in the M 1 receptor (Spalding et al., 1994) . The results suggest that the free carboxyl group of D3.32 is the site of covalent alkylation by AChM at both M 1 and M 2 receptors in addition to another site that is alkylated at a much slower rate with lower affinity.
In contrast, our experiments with BR384 showed marked alkylation of M 1 D105N and M 2 D103N, although the affinity of the aziridinium ion for these mutant receptors was only oneThis article has not been copyedited and formatted. The final version may differ from this version. (Table 1) .
Using hemi-ligands of McN-A343, Valant et al. (2008) showed that 3-chlorophenylcarbamate acts as a negative allosteric modulator of [ 3 H]NMS at the M 2 receptor, whereas tretramethylammonium acts as an agonist, presumably by interacting with D103. A butyne chain connects these groups in McN-A-343, suggesting that the latter interacts with both D103 via its trimethylammonium group and with the allosteric site via its 3-chlorophenyl group.
Molecular modeling showed that the M 2 receptor could accommodate McN-A-343 in this orientation (Valant et al., 2008) , suggesting that BR384 alkylates D103 in addition to at least one other residue.
While the D3.32N mutation decreased the alkylation rate for AChM substantially at both (Lazareno et al., 1993; Figueroa et al., 2008) .
Several investigators have reported how the mutations investigated in this study influence the binding of NMS, ACh and McN-A343 to M 1 and M 2 receptors (Leppik et al., 1994; Schwarz et al., 1995; Vogel et al., 1999) . Our results are consistent with these prior findings. The pK A s of the hydroxyl groups of serine and tyrosine are sufficiently high that it seems unlikely that these residues are alkylated unless they are coordinated by proton withdrawing residues.
Regardless, we cannot rule out the possibility that one of these residues is alkylated because alkylation could be rescued by alkylation of D 3.32 or another residue. To prevent M 2 receptor alkylation by BR384 completely, it is probably necessary to mutate more than one residue.
Determining where a drug binds on a receptor based on how it interferes with the binding of a site-directed electrophile is a powerful approach for discriminating between competitive and highly negatively cooperative interactions. Our results show that AChM and BR384 react covalently with the orthosteric site of the M 2 muscarinic receptor, and hence, that these reactive probes can be used as site-directed electrophiles for the orthosteric site. This useful approach for investigating drug-receptor interactions can be enhanced through the design of other higher affinity electrophiles, and it can be applied to study allosteric interactions at numerous other receptors.
This article has not been copyedited and formatted. The final version may differ from this version. were mutated in this study. Black disks, while lettering, nucleophilic residues lining the central aqueous binding pocket; gray disks, white lettering, nucleophilic residues that are though to be part of a peripheral docking site; light-gray disks, black lettering, acidic residues tethered near the top of the aqueous binding pocket by the disulfide bond linking E2 with the top of TM3; and white disks with black halo, reactive cysteine residues in E3. 
